DeMichiei Robert purchased $98K of ARDT

DeMichiei Robert purchased 11,260 shares of Ardent Health, Inc. (ARDT) at $8.73 on 2026-06-05.

Original reporting
SEC EDGAR · DeMichiei Robert
Published Jun 8, 2026, 4:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDT
Bullish
medium confidence
Mentioned
$ARDT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDTBullishLow
01

Why it matters

The newest concrete fact is the director’s purchase details (shares, price, total value, and post-transaction holdings). This can slightly influence sentiment but does not change fundamentals on its own.

02

Market read

A modest insider-buy disclosure that may support sentiment but is unlikely to drive a sustained repricing without additional company catalysts.

03

What to watch

The filing does not state intent, constraints, or whether the purchase is part of a broader pattern; traders should check for prior Form 4 activity and any concurrent company news.

Relevance 4/10Novelty 8/10Timing: Form 4 filed June 8 (transaction dated June 5)

Background

The filing is an SEC Form 4 insider transaction for Ardent Health, reporting a director’s direct open-market purchase.

Company-level read

Ticker impact

$ARDTBullishMedium confidence
Context

Director DeMichiei Robert bought 11,260 shares of Ardent Health at $8.73/share via an open-market Form 4 filed June 8.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or operational news.

Evidence & confidence

The article is a primary SEC Form 4 showing a director purchase (~$98.3k). While directionally positive, the size and lack of new operating/regulatory information typically constrain price impact.

Market effects

No sector read-through; this is company-specific insider activity without operational details.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (tax/portfolio rebalancing) and may not reflect near-term fundamentals, especially without a 10b5-1 plan.

Key entities

  • Ardent Health, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • DeMichiei Robert

    Director who purchased 11,260 shares on June 5 at $8.73/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDTMed

BofA raises Ardent Health stock price target on acquisition upside

BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.

$ARDTMed

What Ardent Health (ARDT) Said on Its Q3 Earnings Call

Ardent Health (ARDT) reported Q3 earnings, highlighting a 9% increase in urgent care visits and a 400 basis point decline in physician referral leakage. Labor costs fell 4.3% YoY, and the company plans to sell a Kansas hospital for 11x EBITDA. Ardent generated $122M in Q3 operating cash flow and lowered its 2026 capital expenditure guidance. The company remains 85% contracted for 2027 and 75% for 2028, with negotiations described as contentious.

$ARDTHighAI 8/10

Ardent Health (ARDT) Q3 2026 Earnings Call Transcript

Ardent Health (ARDT) reported Q3 2026 adjusted EBITDA of $138M, up 1.5% from prior guidance. Revenue was $1.62B, with adjusted admissions up 2.9%. The company plans to divest a Kansas hospital at 11x EBITDA, enhancing margins by 40bps. Ardent's IMPACT program aims for $70M in savings this year, and it raised its EBITDA guidance midpoint by 1.5%.